UCB to Showcase Immunology Portfolio at EULAR 2012
Complete the form below to unlock access to ALL audio articles.
UCB is sponsoring several data presentations for its immunology portfolio at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology in Berlin, Germany, June 6-9 2012.
“We are pleased to show our continued commitment to improving the lives of those living with autoimmune diseases,” said Professor Dr Iris Loew-Friedrich, Chief Medical Officer and Executive Vice President UCB.
Professor Dr Loew-Friedrich continued, “The breadth of presentations in rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, and osteoporosis illustrate UCB’s ongoing research in these areas.”
In the European Union, certolizumab pegol in combination with methotrexate (MTX) is approved for the treatment of moderate to severe active RA in adult patients inadequately responding to disease-modifying anti-rheumatic drugs (DMARDs) including MTX.
Certolizumab pegol can be given as monotherapy in case of intolerance to MTX or when combined treatment with MTX is inappropriate.
Certolizumab pegol is being investigated in the treatment of psoriatic arthritis and axial spondyloarthritis, and is not approved in these indications.
Epratuzumab is being developed for the treatment of moderate to severe systemic lupus erythematosus (SLE). It is a humanized monoclonal antibody targeting CD22, a B cell-specific protein.
CD22 is considered to be a regulator of B-cell function and these cells are known to contribute to SLE by over-reacting and producing antibodies against the body’s own cells and tissues. Epratuzumab is unlicensed for clinical use.
Olokizumab is being developed for the treatment of patients with moderate to severe RA. It is a humanized monoclonal antibody targeting the IL-6 cytokine. IL-6 is involved in several autoimmune and inflammatory pathways.
Olokizumab is an IL-6 inhibitor that selectively blocks the final assembly of the IL-6 receptor signaling complex. Olokizumab is unlicensed for clinical use.
UCB and Amgen are collaborating on the development of CDP7851/AMG 785 for the treatment of bone-related conditions, including postmenopausal osteoporosis.
CDP7851/AMG 785 is a monoclonal antibody that binds to and inhibits sclerostin, thereby stimulating bone formation while decreasing bone resorption, leading to significant increases in bone mass and bone strength. CDP7851/AMG785 is unlicensed for clinical use.
